Immuron (IMRN) Short-term Investments (2023)

Immuron (IMRN) posted quarterly Short-term Investments of $1.2 million for Q4 2023, down 34.28% on a QoQ basis from $1.8 million in Q2 2023.

Immuron (IMRN) Short-term Investments (2023) Analysis & Trends

Immuron (IMRN) has reported Short-term Investments for 1 consecutive years, with $1.2 million the latest figure, recorded in Q4 2023.

  • Quarterly Short-term Investments changed N/A year-over-year to $1.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.2 million (changed N/A YoY) and the FY2023 annual result came in at $1.2 million, changed N/A from the prior year.
  • Short-term Investments retreated to $1.2 million in Q4 2023 per IMRN's latest filing, from $1.8 million in the prior quarter.
  • Over the last five years, Short-term Investments for IMRN reached as high as $1.8 million in Q2 2023 and fell as low as $1.2 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Immuron 270.20 Mn 258.54 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 1.21 Mn
Jun 30, 2023 1.83 Mn